SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 2
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
  • 3
    Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26: 1932-1940.
  • 4
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-1101.
  • 5
    Poradosu E, Lemmon MA, Keleti D. Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2. Paper presented at: Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract 1645.
  • 6
    Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009; 69: 8967-8976.
  • 7
    Stephenson J, Schreeder M, Waples J, et al. Perifosine, active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI) [abstract]. J Clin Oncol. 2007; 25S. Abstract 15622.
  • 8
    Cho D, Atkins MB, Mier JW. Inhibition of glycogen synthase kinase 3β (GSK3β) enhances the in vitro activity of the Akt inhibitor perifosine in renal cell carcinoma (RCC) cell lines. Paper presented at: Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract 1823.
  • 9
    Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer. 2002; 12: 1615-1621.
  • 10
    Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol. 2010; 28: 5017-5019.
  • 11
    Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
  • 12
    Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial [abstract]. J Clin Oncol. 2011; 29S. Abstract 4503.
  • 13
    Chiarini F, Del Sole M, Mongiorgi S, et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia. 2008; 22: 1106-1116.
  • 14
    Kumar A, Fillmore HL, Kadian R, Broaddus WC, Tye GW, Van Meter TE. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Mol Cancer Res. 2009; 7: 1813-1821.
  • 15
    Elrod HA, Lin YD, Yue P, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther. 2007; 6: 2029-2038.
  • 16
    David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res. 2008; 14: 5090-5098.
  • 17
    Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res. 2008; 68: 9394-9403.
  • 18
    Celeghini C, Voltan R, Rimondi E, Gattei V, Zauli G. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. Invest New Drugs. 2011; 29: 392-395.
  • 19
    Wang FZ, Fei HR, Li XQ, Shi R, Wang DC. Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells [published online ahead of print July 19, 2011]. Mol Cell Biochem. 2011.
  • 20
    Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010; 9: 963-975.
  • 21
    Holland WS, Tepper CG, Pietri JE, et al. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012; 69: 185-194.
  • 22
    Pitter KL, Galban CJ, Galban S, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma [serial online]. PLoS One. 2011; 6: e14545.